TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference
MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 12th, 2023.
Related news for (TELA)
- TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
- TELA Bio Appoints Jeffrey Blizard as President
- TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TELA Bio to Announce First Quarter 2025 Financial Results